Published in Br J Clin Pharmacol on March 01, 1981
The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs. Br J Clin Pharmacol (1981) 0.80
Assessment of anti-psychotic drugs. Br J Clin Pharmacol (1981) 0.75
David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011. Br J Clin Pharmacol (2012) 0.75
Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment. Br J Clin Pharmacol (1985) 0.75
Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (1962) 18.89
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol (1976) 1.31
Influence of lysolecithin on platelet aggregation initiated by 5-hydroxytryptamine. Nat New Biol (1973) 1.26
Release of 5-hydroxytryptamine from blood platelets. J Pharm Pharmacol (1965) 1.15
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine. Br J Pharmacol (1980) 0.94
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
Stigmatisation of people with mental illnesses. Br J Psychiatry (2000) 7.24
Diary keeping in asthma: comparison of written and electronic methods. BMJ (1993) 6.77
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Sequence analysis of ultraviolet-induced mutations in M13lacZ hybrid phage DNA. J Mol Biol (1984) 2.66
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Specificity of the FTA-ABS test for syphilis. JAMA (1969) 2.41
In vitro lymphocyte response to Treponema refringens im human syphilis. Infect Immun (1974) 2.27
Implications of supervision registers in psychiatry. BMJ (1994) 2.22
The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens (2004) 2.13
Severe agoraphobia: a controlled prospective trial of behaviour therapy. Br J Psychiatry (1966) 2.12
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill (2009) 2.01
The pathogenesis of Dieulafoy's gastric erosion. Am J Gastroenterol (1984) 1.97
Parenteral cephaloridine treatment of patients with early syphilis. Arch Intern Med (1968) 1.94
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
Treatment of gonorrhea with spectinomycin hydrochloride: comparison with standard penicillin schedules. Antimicrob Agents Chemother (1972) 1.86
Misuse of temazepam. BMJ (1991) 1.82
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Desensitization and psychotherapy in the treatment of phobic states: a controlled inquiry. Br J Psychiatry (1967) 1.67
Treatment of gonorrhoea with a single oral dose of minocycline. Br J Vener Dis (1971) 1.63
Modified leucotomy in severe agoraphobia: a controlled serial inquiry. Br J Psychiatry (1966) 1.61
Attachment of gonococci to sperm. Influence of physical and chemical factors. Br J Vener Dis (1976) 1.60
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Body image: gender, ethnic, and age differences. J Soc Psychol (2000) 1.50
Depression of growth in hyperactive children on stimulant drugs. N Engl J Med (1972) 1.50
Mass cultivation of avirulent Treponema pallidum (Nichols). Microbios (1971) 1.49
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The parasitome of the phytonematode Heterodera glycines. Mol Plant Microbe Interact (2003) 1.48
Paternity Testing Commission of the International Society of Forensic Genetics. Recommendations on genetic investigations in paternity cases. Int J Legal Med (2003) 1.46
Influence of wind on ultraviolet injury. Arch Dermatol (1974) 1.44
British Dietetic Association evidence-based guidelines for the dietary management of Crohn's disease in adults. J Hum Nutr Diet (2013) 1.44
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
The FTA-ABS test in dark-field-positive primary syphilis. JAMA (1974) 1.43
Closure of a bronchopleural fistula with bronchoscopic instillation of tetracycline. Chest (1991) 1.43
Who will practise emergency medicine? Survey of family medicine graduates. Can Fam Physician (1993) 1.42
Kawasaki disease in Australia, 1993-95. Arch Dis Child (1998) 1.42
Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. J Clin Invest (1985) 1.40
Hypnosis and desinsitization for Phobias: a controlled prospective trial. Br J Psychiatry (1968) 1.40
Training of staff for the delivery of PET/CT services in the UK. Nucl Med Commun (2006) 1.39
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Persistent atrial fibrillation following central venous cannulation. Paediatr Anaesth (1999) 1.37
Different ages of onset in varieties of phobia. Am J Psychiatry (1966) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Isolation of genes encoding the Neurospora vacuolar ATPase. Analysis of vma-2 encoding the 57-kDa polypeptide and comparison to vma-1. J Biol Chem (1988) 1.33
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol (1976) 1.31
International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol (2003) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Phase-shifting effects of bright morning light as treatment for delayed sleep phase syndrome. Sleep (1990) 1.25
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility. Am J Public Health (2000) 1.21
A profile of putative parasitism genes expressed in the esophageal gland cells of the root-knot nematode Meloidogyne incognita. Mol Plant Microbe Interact (2003) 1.20
The immunology of syphilis. Int J Dermatol (1976) 1.18
Human neutrophils exhibit disparate chemotactic factor gene expression. Biochem Biophys Res Commun (1990) 1.18
Physiological and environmental control of Gram negative bacteria on skin. Br J Dermatol (1975) 1.18
Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol (1989) 1.17
Signal peptide-selection of cDNA cloned directly from the esophageal gland cells of the soybean cyst nematode Heterodera glycines. Mol Plant Microbe Interact (2001) 1.17
Transvestism and fetishism: clinical and psychological changes during faradic aversion. Br J Psychiatry (1967) 1.17
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep (1999) 1.17
Terra firma-forme dermatosis. Arch Dermatol (1987) 1.17
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol (2004) 1.16
Neurosyphilis, the search for adequate treatment. A review and report of a study using benzathine penicillin G. Arch Dermatol (1966) 1.15
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
Resistance and serological changes in rabbits immunized with virulent Treponema pallidum sonicate. Acta Derm Venereol (1971) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
Virus infections in bats. Monogr Virol (1974) 1.15
Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol (2010) 1.14
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Validity of the VDRL test on cerebrospinal fluid contaminated by blood. Br J Vener Dis (1971) 1.12
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
The FTA-ABS test for syphilis. Performance in 1,033 patients. Br J Vener Dis (1966) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychol Med (1976) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Organization of cytokeratin bundles by desmosomes in rat mammary cells. J Cell Biol (1986) 1.10
Bacterial flora. The role of environmental factors. J Invest Dermatol (1969) 1.09